NCT03769415View on ClinicalTrials.gov

Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA

NARecruitingINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

November 6, 2018

Primary Completion Date

December 15, 2030

Study Completion Date

December 15, 2030

Conditions
Breast Cancer
Interventions
DEVICE

Intrinsic Subtyping of Primary Breast Cancer

Primary breast tissue will be sent for Nanostring PAM50 Testing to determine intrinsic subtype

Trial Locations (2)

27599

RECRUITING

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

27607

RECRUITING

UNC Rex Healthcare, Raleigh

Sponsors
All Listed Sponsors
collaborator

Veracyte, Inc.

INDUSTRY

collaborator

Breast Cancer Research Foundation

OTHER

lead

UNC Lineberger Comprehensive Cancer Center

OTHER